Literature DB >> 10688034

Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.

L L Xu1, V Srikantan, I A Sesterhenn, M Augustus, R Dean, J W Moul, K C Carter, S Srivastava.   

Abstract

PURPOSE: NKX3.1, a member of the family of homeobox genes, exhibits prostate tissue specific expression and appears to play a role in mouse prostate development. Rapid induction of NKX3.1 gene expression in response to androgens has also been described. On the basis of the established role of androgens in prostatic growth and differentiation and studies showing an association of aberrant homeobox gene expression with the neoplastic process, we hypothesize that alterations of NKX3.1 gene expression play a role in prostate tumorigenesis.
MATERIALS AND METHODS: NKX3.1 expression was analyzed in matched, microdissected normal and tumor tissues from 52 primary prostate cancer specimens from radical prostatectomy by semiquantitative RT-PCR and in situ hybridization and correlated with the clinicopathologic features. NKX3.1 expression was quantified as differential expression between matched tumor and normal tissues and was grouped as overexpression in tumor tissue, reduced expression in tumor tissue and no change between tumor and normal tissues. Androgen regulation of NKX3.1 expression was also studied in LNCaP cells. Androgen receptor (AR) expression in prostate tumor and normal tissue was correlated with NKX3.1 expression.
RESULTS: Comparison of NKX3.1 expression between normal and tumor tissues revealed overexpression in 31% tumor specimens (16 of 52), decreased expression in 21% tumor specimens (11 of 52) and no change in 48% specimens (25 of 52). When these expression patterns were stratified by organ confined and non-organ-confined tumor, a higher percentage of patients exhibited NKX3.1 overexpression in non-organ confined tumor (40%) versus organ confined tumor (22%). Elevated NKX3.1 expression significantly correlated with tumor volume and serum prostate specific antigen (PSA) level in the NKX3.1 overexpression group (p<0.05). Metastatic prostate cancer cell lines did not exhibit mutations in the protein coding sequence of NKX3.1. Additionally, the NKX3.1 expression correlated with AR expression (p<0.01) in vivo in human prostate tissues. Comparison of PSA and NKX3.1 expression in response to androgen revealed a rapid androgen mediated induction of NKX3.1 expression in LNCaP cells. In situ hybridization analysis of representative specimens confirmed RT-PCR observations.
CONCLUSIONS: These results suggest an association of NKX3.1 with a more aggressive phenotype of carcinoma of the prostate. Correlation of AR expression with NKX3.1 in human prostate tissues underscores the androgen regulation of NKX3.1 in the physiologic context of human prostate tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688034

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

1.  Nkx3.1 functions as para-transcription factor to regulate gene expression and cell proliferation in non-cell autonomous manner.

Authors:  Jian Zhou; Li Qin; Jean Ching-Yi Tien; Li Gao; Xian Chen; Fen Wang; Jer-Tsong Hsieh; Jianming Xu
Journal:  J Biol Chem       Date:  2012-03-31       Impact factor: 5.157

2.  NKX3.1 as a marker of prostatic origin in metastatic tumors.

Authors:  Bora Gurel; Tehmina Z Ali; Elizabeth A Montgomery; Shahnaz Begum; Jessica Hicks; Michael Goggins; Charles G Eberhart; Douglas P Clark; Charles J Bieberich; Jonathan I Epstein; Angelo M De Marzo
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

3.  Gene expression profiles in the PC-3 human prostate cancer cells induced by NKX3.1.

Authors:  Pengju Zhang; Wenwen Liu; Ju Zhang; Hengyun Guan; Weiwen Chen; Xing Cui; Qingwei Liu; Anli Jiang
Journal:  Mol Biol Rep       Date:  2009-05-22       Impact factor: 2.316

4.  Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient.

Authors:  Shaniece Theodore; Starlette Sharp; Jianjun Zhou; Timothy Turner; Hongzhen Li; Jun Miki; Youngmi Ji; Vyomesh Patel; Clayton Yates; Johng S Rhim
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

5.  The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus.

Authors:  Kouhei Sakurai; Brian J Reon; Jordan Anaya; Anindya Dutta
Journal:  Mol Cancer Res       Date:  2015-02-20       Impact factor: 5.852

Review 6.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

7.  Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor.

Authors:  Li Xin; Michael A Teitell; Devon A Lawson; Andrew Kwon; Ingo K Mellinghoff; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

8.  NKX3.1 is regulated by protein kinase CK2 in prostate tumor cells.

Authors:  Xiang Li; Bin Guan; Sam Maghami; Charles J Bieberich
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.

Authors:  Tsuyoshi Iwata; Denise Schultz; Jessica Hicks; Gretchen K Hubbard; Laura N Mutton; Tamara L Lotan; Carlise Bethel; Matthew T Lotz; Srinivasan Yegnasubramanian; William G Nelson; Chi V Dang; MengMeng Xu; Uzoma Anele; Cheryl M Koh; Charles J Bieberich; Angelo M De Marzo
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

10.  NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.

Authors:  Rebecca J Asch-Kendrick; Mark A Samols; Mohammed T Lilo; Andrea P Subhawong; Rajni Sharma; Peter B Illei; Pedram Argani; Ashley Cimino-Mathews
Journal:  J Clin Pathol       Date:  2014-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.